We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Scientists Establish New Guidelines for Improved MRI Prostate Cancer Diagnosis

By MedImaging International staff writers
Posted on 23 Dec 2014
Print article
A new scientific partnership has the goal of accelerating the transfer of high quality prostate magnetic resonance imaging (MRI) findings from the laboratory to the clinic.

The Joint Steering Committee of the American College of Radiology (ACR; Reston, VA, USA), AdMeTech Foundation (Boston, MA, USA),and the European Society of Urogenital Radiology (ESUR; Vienna, Austria) released new clinical imaging guidelines to help in the early detection and treatment of prostate cancer. The new guidelines were announced at the meeting of AdMeTech’s International Prostate MRI Working Group (AdMeTech’s Group), held in conjunction with the annual meeting of the Radiologic Society of North America (RSNA), November 30 to December 5, 2014, in Chicago (IL, USA).

The Joint Steering Committee developed Prostate Imaging Reporting and Data System Version-2, (PI-RADSv2) as global guidelines for high quality multiparametric prostate magnetic resonance imaging (MRI) service. This research has built on the initial PI-RADS standardization, which was recommended by AdMeTech’s Group in 2010 and created by ESUR in 2011. PI-RADSv2 has defined minimum technical requirements for creating images and in coordination with RSNA’s Radiologic Lexicon Committee, set standards for communicating the risk and location of aggressive prostate cancer. These clinical guidelines were established to accelerate wide-scale transfer of the high quality clinical service from the few leading research centers to the international medical community.

Modeled after similar mammography developments that transformed breast cancer care, AdMeTech’s Group has brought together global specialists in medicine and industry who have been working in cooperation to expedite the advancement, testing, standardization and implementation of prostate MRI since 2007. PI-RADSv2 will become available on ACR's website in December 2014.

Prostate cancer is the most common major cancer in the United States and the second deadly lethal cancer in men. While prostate cancer has become more common than even breast cancer, men do not have accurate diagnostic tools analogous to life-saving mammograms. The PI-RADSv2 guidelines for prostate MRI service will address the central needs in patient care (1) To improve early identification of life-threatening prostate cancer by replacing “blind” and random biopsies (which fail to analyze over 99% of the prostate) with image-guided, precisely targeted procedures; (2) to reduce overdiagnosis of benign and dormant diseases, which currently leads to unnecessary biopsies in up to one million men and unnecessary treatment in over 90,000 men each year; and, lastly, (3) to guide selection of the most effective treatment.

“PI-RADSv2 builds on the tremendous success of ACR’s Breast Imaging Reporting and Data System [BI-RADS] that has improved breast cancer detection and treatment worldwide. This new system, which was initiated by AdMeTech’s Group, expands and improves on the original work by ESUR and continues radiology's history of working collaboratively to save lives and make health care more efficient,” said Jeffrey Weinreb, MD, professor of radiology at Yale University (New Haven, CT, USA) and co-chair of the Joint Steering Committee.

“PI-RADSv2 is a major step forward in the global standardization of prostate MRI, and will result in fast and reliable implementation of high quality diagnostic examinations all over the world. This will have a tremendously positive effect on the quality of patient care,” said Jelle Barentsz, MD, professor of radiology at Radboud University (The Netherlands) and co-chair of the Joint Committee.

“The urgent need for the advancement of prostate cancer diagnosis has been highlighted by the bi-partisan National Prostate Cancer Council Act, recently introduced by US Senators Barbara Boxer and Jeff Sessions,” said Dr. Faina Shtern, CEO of AdMeTech Foundation, chair of the International Prostate MRI Working Group and a member of the Joint Steering Committee. “PI-RADS global guidelines for high quality prostate MRI represent a groundbreaking development in achieving the ultimate goal of this legislation—to empower physicians and patients in making fully informed and individualized decisions on healthcare options.”

The ACR is a US professional organization serving more than 34,000 radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of radiology and the delivery of wide-ranging health care services.

AdMeTech Foundation is a nonprofit organization focused on ending the prostate cancer crisis. Through its Manogram Project, the organization provides global leadership in research, education, awareness, and advocacy to facilitate the advances in prostate cancer care and their transfer to clinics. AdMeTech’s International Prostate MRI Working Group integrates expertise and resources of the top scientific laboratories into a comprehensive research program.

The European Society of Urogenital Radiology (ESUR) was founded in 1990, to promote high quality science and clinical practice of urogenital radiology. Members of the ESUR are the world-leading radiologists in urogenital radiology. This society was especially successful in establishing guidelines on the safe use of contrast media and on female genital imaging, and more recently on standardization of prostate MRI.

Related Links:

Joint Steering Committee of the American College of Radiology 
AdMeTech Foundation 
European Society of Urogenital Radiology


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Under Table Shield
3 Section Double Pivot Under Table Shield
New
Self-Driving Mobile C-arm
CIARTIC Move
New
Breast Imaging Workstation
SecurView

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.